These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. First In Class ( Mingle D; Ospanov M; Radwan MO; Ashpole N; Otsuka M; Ross SA; Walker L; Shilabin AG; Ibrahim MA Med Chem Res; 2021 Jan; 30(1):98-108. PubMed ID: 33776384 [TBL] [Abstract][Full Text] [Related]
25. Positive Allosteric Modulation of CB1 and CB2 Cannabinoid Receptors Enhances the Neuroprotective Activity of a Dual CB1R/CB2R Orthosteric Agonist. Polini B; Cervetto C; Carpi S; Pelassa S; Gado F; Ferrisi R; Bertini S; Nieri P; Marcoli M; Manera C Life (Basel); 2020 Dec; 10(12):. PubMed ID: 33302569 [TBL] [Abstract][Full Text] [Related]
26. Cannabinoid receptor subtypes 1 and 2 mediate long-lasting neuroprotection and improve motor behavior deficits after transient focal cerebral ischemia. Schmidt W; Schäfer F; Striggow V; Fröhlich K; Striggow F Neuroscience; 2012 Dec; 227():313-26. PubMed ID: 23069763 [TBL] [Abstract][Full Text] [Related]
27. Expression and function of cannabinoid receptors CB1 and CB2 and their cognate cannabinoid ligands in murine embryonic stem cells. Jiang S; Fu Y; Williams J; Wood J; Pandarinathan L; Avraham S; Makriyannis A; Avraham S; Avraham HK PLoS One; 2007 Jul; 2(7):e641. PubMed ID: 17653268 [TBL] [Abstract][Full Text] [Related]
28. Differential upregulation of the cannabinoid CB₂ receptor in neurotoxic and inflammation-driven rat models of Parkinson's disease. Concannon RM; Okine BN; Finn DP; Dowd E Exp Neurol; 2015 Jul; 269():133-41. PubMed ID: 25895887 [TBL] [Abstract][Full Text] [Related]
33. Type-2 cannabinoid receptors in neurodegeneration. Bisogno T; Oddi S; Piccoli A; Fazio D; Maccarrone M Pharmacol Res; 2016 Sep; 111():721-730. PubMed ID: 27450295 [TBL] [Abstract][Full Text] [Related]
34. Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications. Fernández-Ruiz J; Moro MA; Martínez-Orgado J Neurotherapeutics; 2015 Oct; 12(4):793-806. PubMed ID: 26260390 [TBL] [Abstract][Full Text] [Related]
35. Endocannabinoids and the gastrointestinal tract: what are the key questions? Sanger GJ Br J Pharmacol; 2007 Nov; 152(5):663-70. PubMed ID: 17767170 [TBL] [Abstract][Full Text] [Related]
36. Endocannabinoids and cannabinoid receptor genetics. Onaivi ES; Leonard CM; Ishiguro H; Zhang PW; Lin Z; Akinshola BE; Uhl GR Prog Neurobiol; 2002 Apr; 66(5):307-44. PubMed ID: 12015198 [TBL] [Abstract][Full Text] [Related]
37. Therapeutic potential of cannabinoid receptor ligands: current status. Singh J; Budhiraja S Methods Find Exp Clin Pharmacol; 2006 Apr; 28(3):177-83. PubMed ID: 16810344 [TBL] [Abstract][Full Text] [Related]
38. Understanding the role of heteroreceptor complexes in the central nervous system. Fuxe K; Borroto-Escuela D; Fisone G; Agnati LF; Tanganelli S Curr Protein Pept Sci; 2014; 15(7):647. PubMed ID: 25256022 [TBL] [Abstract][Full Text] [Related]
39. Computational investigation on the binding modes of Rimonabant analogs with CB1 and CB2. Liu C; Yuan C; Wu P; Zhu C; Fang H; Wang L; Fu W Chem Biol Drug Des; 2018 Sep; 92(3):1699-1707. PubMed ID: 29797785 [TBL] [Abstract][Full Text] [Related]